Researchers at the University of Illinois at Chicago and Queensland University of Technology of Australia, have developed a device that can isolate individual cancer cells from patient blood samples.
The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans. The findings are reported in the journal Microsystems & Nanoengineering.
“This new microfluidics chip lets us separate cancer cells from whole blood or minimally-diluted blood,” said Ian Papautsky, the Richard and Loan Hill Professor of Bioengineering in the UIC College of Engineering and corresponding author on the paper. “While devices for detecting cancer cells circulating in the blood are becoming available, most are relatively expensive and are out of reach of many research labs or hospitals. Our device is cheap, and doesn’t require much specimen preparation or dilution, making it fast and easy to use.”
The ability to successfully isolate cancer cells is a crucial step in enabling liquid biopsy where cancer could be detected through a simple blood draw. This would eliminate the discomfort and cost of tissue biopsies which use needles or surgical procedures as part of cancer diagnosis. Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs.
However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities. For many cancers, circulating cells are present at levels close to one per 1 billion blood cells. “A 7.5-milliliter tube of blood, which is a typical volume for a blood draw, might have ten cancer cells and 35-40 billion blood cells,” said Papautsky. “So we are really looking for a needle in a haystack.”
Microfluidic technologies present an alternative to traditional methods of cell detection in fluids. These devices either use markers to capture targeted cells as they float by, or they take advantage of the physical properties of targeted cells — mainly size — to separate them from other cells present in fluids.
Papautsky and his colleagues developed a device that uses size to separate tumor cells from blood. “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses ‘sticky’ tags that capture the right cell type as it goes by,” said Papautsky. “Affinity separation also requires a lot of advanced purification work which size separation techniques don’t need.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Amgen to Collaborate on Development of Lung Cancer Drugon January 13, 2020 at 3:27 pm
Amgen Inc. on Monday announced it will collaborate with Guardant Health Inc. and Qiagen N.V. to further its research on AMG 510, a pipeline drug designed to treat metastatic lung cancer. According to ...
- Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Canceron January 13, 2020 at 12:20 pm
today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V.
- Guardant Health teams up with Amgen to develop CDx teston January 13, 2020 at 11:47 am
Guardant Health (GH-2.2%) will collaborate with Amgen (AMGN-1%) on developing a blood-based companion diagnostic (CDx) test for candidate AMG 510. GH will pursue regulatory approvals in the U.S., ...
- JPM: Roche, Illumina unveil 15-year cancer diagnostic tie-upon January 13, 2020 at 10:45 am
Join us for this webinar as we attempt to answer these questions. Roche plans to develop, manufacture and commercialize its Avenio cancer test kits for both tissue and blood samples, while Illumina ...
- The First Step to Detect Colorectal Cancer Early: RedEye Heme Detection System Enables Immunochemical Fecal Occult Blood Test (iFOBT) at Homeon January 13, 2020 at 7:30 am
TAIPEI, Jan. 13, 2020 /PRNewswire/ -- RedEye and other notable homegrown startups led by Taiwan Tech Arena (TTA) had showcased their innovative solutions and sought for global cooperation at CES 2020.
- The war against canceron January 13, 2020 at 6:30 am
One solution is a push for greater consistency worldwide in terms of cancer prevention, diagnosis, and effective treatment.
- Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trialon January 13, 2020 at 3:52 am
Springworks Therapeutics and Allogene Therapeutics have agreed to collaborate on a clinical trial to test a combination of an investigational cancer drug from each biotech in patients with ...
- Cancer Diagnostics Market 2020 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 – Market Research Engineon January 13, 2020 at 2:29 am
New York, January 13, 2020: The land investigation of cutting edge disease diagnostics market isolates it into North America, Europe, Asia-Pacific, Latin America and MEA. In 2015, North America ...
- Lower levels of lymphocyte blood cells may indicate increased risk of deathon January 12, 2020 at 11:57 pm
Lymphopenia is often detected during routine blood tests, and patients are not usually referred for further investigation ... a 1.6-fold increase in the risk of death from any cause and a 1.5- to ...
- Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Canceron January 12, 2020 at 4:00 pm
REDWOOD CITY, Calif. and PITTSBURGH, Pa., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and NRG Oncology, ...
via Bing News